Business
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery,
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its third quarter 2020 financial results and provide a business update after market close on Thursday, November 5, 2020. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m. ET (2:00 p.m. PT/10:00 p.m. GMT) that day.\n\n \n \n \n \n \n \n\n \nConference Call Information\nTo participate in the live call by telephone, please dial (855) 296-9648 from the US or (920) 663-6266 for international callers, using the confirmation code 1269525. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investor Relations section, Presentations and Events. \nA replay of the conference call will be available on Theravance Biopharma's website for 30 days through December 5, 2020. An audio replay will also be available through 8:00 p.m. ET on November 12, 2020 by dialing (855) 859-2056 from the US, or (404) 537-3406 for international callers, and then entering confirmation code 1269525.\nAbout Theravance Biopharma\nTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.\nIn pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered p...